Molecular Phenotype Changes and Personalized Treatment for CRPC

NCT02208583 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Hormone Refractory Prostate Cancer

Interventions

DRUG: Docetaxel & Prednisone
DRUG: DP & Targeted drugs
DRUG: cisplatin & Etoposide
DRUG: EP & Targeted drugs

Sponsor

Tianjin Medical University Cancer Institute and Hospital